Bladder Cancer - Results from #180

REVIEW UroToday

Molecular biomarkers of progression in non-muscle-invasive bladder cancer - beyond conventional risk stratification. August 8, 2024

Developments in conservative treatment for BCG-unresponsive non-muscle invasive bladder cancer. August 7, 2024

Role of 64CuCl2 PET/CT in Detecting and Staging Muscle-Invasive Bladder Cancer: Comparison with Contrast-Enhanced CT and 18F-FDG PET/CT. August 7, 2024

Efficacy of Gemcitabine and Docetaxel for Treatment of Micropapillary Urothelial Carcinoma - Expert Commentary August 6, 2024

An Extremely Rare Case of a 24-Year-Old Female Diagnosed With High-Grade Muscle-Invasive Urothelial Carcinoma in the Bladder. August 6, 2024

Invasive Mycobacterium bovis Infection Outside the Genitourinary Tract Following Bacille Calmette-Guerin Therapy for Non-muscle Invasive Bladder Cancer. August 6, 2024

Immunotherapy Plus Chemotherapy Versus Chemotherapy Alone as First-Line Treatment for Advanced Urothelial Cancer: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. August 6, 2024

Platinum-based chemotherapy induces opposing effects on immunotherapy response-related spatial and stromal biomarkers in the bladder cancer microenvironment. August 5, 2024

The accuracy and quality of image-based artificial intelligence for muscle-invasive bladder cancer prediction. August 5, 2024

Sequential Endoluminal Gemcitabine and Cabazitaxel with Intravenous Pembrolizumab as a Bladder-Preserving Strategy for Docetaxel-Unresponsive Non-Muscle Invasive Urothelial Carcinoma Following Transurethral Resection of Bladder Tumor. August 5, 2024

Prognostic role of the neutrophil/lymphocyte ratio in high-risk BCG-naïve non-muscle-invasive bladder cancer treated with intravesical gemcitabine/docetaxel. August 2, 2024

National Surgical Quality Improvement Program audit of contemporary perioperative care for radical cystectomy. August 2, 2024

Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysis. August 2, 2024

Assessing the safety of bladder-preserving therapy as an alternative to surgical intervention in elderly patients with muscle invasive bladder cancer. August 1, 2024

Prospective non-randomized comparison of transurethral laser en bloc resection vs. conventional resection of bladder tumors larger than 3 cm. August 1, 2024

Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab Versus Pembrolizumab Therapy. August 1, 2024

The Effect of GLP1R Agonists on Bladder, Kidney, and Prostate Cancer Risk - Expert Commentary July 31, 2024

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study. July 31, 2024

Mitomycin C vs. Bacillus Calmette-Guerin for treatment of intermediate-risk nonmuscle invasive bladder cancer patients-A comparative analysis from a single center. July 31, 2024

Advances, recognition, and interpretation of molecular heterogeneity among conventional and subtype histology of urothelial carcinoma (UC): a survey among urologic pathologists and comprehensive review of the literature. July 31, 2024

Page 10 of 517